Earlier this year, BioSpace tallied up the hottest U.S. biotech start-ups in their NextGen Bio Class of 2020 – Anthos Therapeutics was ranked #2. Anthos focuses on developing drugs for cardiovascular disease, especially for high-risk patients. Their goal? To develop next-generation anticoagulants that don’t have the bleeding risks current blood thinners have. Their lead drug is also long acting, meaning patients may only need to take it monthly versus daily.
If their drug pans out in clinical trials, it could be great news for the millions of people affected by cardiovascular diseases each year. Heart disease is the leading cause of death in the U.S., killing 647,000 Americans each year (about 1 in 4 of all U.S. deaths). Thrombosis, when a blood clot blocks the blood vessel, can cause heart attacks or strokes, which together cause a quarter of all deaths worldwide.
“Forty-five percent of people at risk of thrombosis are untreated or sub optimally...
S&P500 | |||
---|---|---|---|
VIX | |||
Eurostoxx50 | |||
FTSE100 | |||
Nikkei 225 | |||
TNX (UST10y) | |||
EURUSD | |||
GBPUSD | |||
USDJPY | |||
BTCUSD | |||
Gold spot | |||
Brent | |||
Copper |
- Top 50 publishers (last 24 hours)